- Subject index
With escalating healthcare costs, changes to the regulatory control on pharmaceutical industries and the inevitable adjustments made in policies and investment in healthcare there is enormous interest in the commercial as well as the scientific aspects of today's healthcare industry.
The SAGE Handbook of Healthcare provides an authoritative analysis of the current (and anticipated) developments in the global healthcare industries. Providing a unique perspective that interfaces between the science and business aspects, it combines information on the latest scientific developments with applied, commercial business data from the global marketplace.
The Handbook focuses on the aspects of paramount importance in the healthcare sector: Pharmacoeconomics; Pharmacogenomics; Therapeutics; Diagnostics
Areas covered include: The role of nanotechnology, genomics and cell therapy in medicine; Diagnostics; Biomarkers and technological advances; Case studies in oncology ...
Chapter 27: Advances Imminent in Antiangiogenesis Therapeutics
Advances Imminent in Antiangiogenesis Therapeutics
Angiogenesis inhibitors have interested cancer researchers since 1971, when scientist and angiogenesis pioneer Judah Folkman first presented his finding in the New England Journal of Medicine that tumor growth depends on angiogenesis. Despite many efforts to develop angiogenesis inhibitors, this class of drugs has experienced a long and difficult road to market. After more than 30 years of research, angiogenesis inhibitors finally experienced a series of breakthroughs in 2004 and 2005, which began with the approval of Genentech's bevacizumab (Avastin).
The Food and Drug Administration's (FDA's) approval of bevacizumab for colon and rectum cancer in 2004 marked the entry of a new class of powerful drugs into the cancer market. Shortly thereafter, the FDA approved Eyetech Pharmaceuticals' ...